Kala Pharmaceuticals GAAP EPS of -$0.38, revenue of $2.1M

Aug. 11, 2022 7:06 AM ETKala Pharmaceuticals, Inc. (KALA)By: Meghavi Singh, SA News Editor
  • Kala Pharmaceuticals press release (NASDAQ:KALA): Q2 GAAP EPS of -$0.38.
  • Revenue of $2.1M (-31.1% Y/Y).
  • As of June 30, 2022, Kala had cash, cash equivalents and short-term investments of $44.6M, compared to $92.1M of cash and cash equivalents as of December 31, 2021.
  • Based on its current plans, Kala anticipates that its cash resources as of June 30, 2022, together with the net proceeds from the Alcon transaction and associated reduction in operating expenses, will enable it to fund its operations into the second quarter of 2024.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.